Back to Search
DIRK KIEBACK, MD
MD
Gynecologic Oncology Physician
NPI: 1417037789Individual
Specialties, Licenses & Credentials
Gynecologic Oncology PhysicianPrimary
Obstetrics & Gynecology — Gynecologic Oncology
Code: 207VX0201X
41336(TX)
Research & Publications (20)
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
PMID 19364653·Breast·2009
4-observational
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
PMID 19218306·Ann Oncol·2009
4-observational
Post-cesarean adhesions--are they a unique entity?
PMID 18609356·J Matern Fetal Neonatal Med·2008
3-trial
Society of gynecologic oncologists position paper: breast cancer care.
PMID 18589209·Gynecol Oncol·2008
8-other
Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
PMID 16360811·Gynecol Oncol·2006
8-other
Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma.
PMID 15726651·J Pathol·2005
8-other
A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.
PMID 15579801·J Clin Endocrinol Metab·2004
7-preclinical
Functional characterization of somatic point mutations of the human estrogen receptor alpha (hERalpha) in adenomyosis uteri.
PMID 15475371·Mol Hum Reprod·2004
7-preclinical
Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.
PMID 15347897·Onkologie·2004
5-case
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
PMID 14998846·Ann Oncol·2004
3-trial
Survival after relapse in patients with endometrial cancer: results from a randomized trial. C.L. Creutzberg, W.L.J. van Putten, P.C. Koper, et al., Gynecologic Oncology 89 (2003) 201-209.
PMID 14751192·Gynecol Oncol·2004
8-other
Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer.
PMID 14612905·Br J Cancer·2003
8-other
European experience with a novel noninvasive sensor for intra-amniotic or extra-amniotic evaluation of fetal oxygen saturation.
PMID 12969777·J Soc Gynecol Investig·2003
8-other
A mutated progesterone receptor allele is more prevalent in unexplained infertility.
PMID 12969718·Fertil Steril·2003
8-other
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
PMID 12881384·Ann Oncol·2003
3-trial
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
PMID 12796366·Clin Cancer Res·2003
8-other
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
PMID 12409327·J Clin Oncol·2002
3-trial
Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
PMID 12119458·Onkologie·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6620 MAIN ST, SUITE 1450
HOUSTON, TX 77030 - Phone
- (713) 798-7500
Quick Facts
- NPI
- 1417037789
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile